High myopia is a major cause of legal blindness in many developed countries, affecting 2% of the general population. Myopic maculopathy, mainly in the form of subfoveal choroidal neovascularisation (CNV), is the most common cause of vision loss in patients with high myopia. The appearance of lacquer cracks and the presence of high levels of vascular endothelial growth factor and pigment epithelium-derived factor¹ are probably involved in the development of myopic CNV. These findings have given way to new theories and approaches to the treatment of myopic CNV.

Different therapeutic approaches have been tried for this condition. Photocoagulation² and surgical removal of subfoveal or juxtafoveal myopic CNV³ are no longer performed because of poor final visual acuity. During the past few years, the two main approaches to subfoveal myopic CNV have been macular translocation⁴ and photodynamic therapy (PDT). PDT has been a major advance in the management of this condition after the good results achieved by the Verteporfin in Photodynamic 1 Study.^5,6 The response of myopic CNV to PDT is considerably better than that of age-related macular degeneration (AMD), requiring less PDT sessions and resulting in better final visual acuity.⁷ This is probably related to the aetiopathogenic mechanism of myopic CNV, …